Phase I Study of PollenVax in Patients With Mugwort Pollen-Induced Allergic Rhinitis

Summary

This Phase I randomized, double-blind, placebo-controlled clinical trial evaluates the safety and tolerability of PollenVax, a novel recombinant allergen-based vaccine for allergen-specific immunotherapy, in adult patients with mugwort pollen-induced allergic rhinitis.

Timeline

Start

2025-11-22

Primary completion

2026-01-16

Completion

2026-01-16

Publications

• Results Tabynov K, Tailakova E, Rakhmatullayeva G, Bolatbekov T, Lim YH, Fomin G, Babayeva M, Valenta R, Tabynov K. Comparison of rArt v 1-based sublingual and subcutaneous immunotherapy in a murine model of asthma. NPJ Vaccines. 2025 Apr 2;10(1):66. doi: 10.1038/s41541-025-01112-1.
• Nurpeissov T, Tabynov K, Zhubanturliyeva A, Nurpeissov T, Khan V, Seidakhmetov O, Yessimova B, Sarsenbayeva G, Tailakova E, Bolatbekov T, Sergazina A, Akhtemova N, Rakhmatullayeva G, Yelchibayeva L, Shorayeva K, Yershebulov Z, Petrovsky N, Tabynov K. Ultra-short recombinant Art v 1 immunotherapy induces rapid immune modulation in mugwort allergy: A Phase I trial. Allergol Int. 2026 Jun 23:S1323-8930(26)00076-6. doi: 10.1016/j.alit.2026.05.010. Online ahead of print.

Drugs

Indications